A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional structures.
All News
Article
Article
Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.
Article
Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.
Article
Dr. Jack Cush reviews the news, journal articles and missed quiz questions.
Article
Dr. Jack Cush reviews safety of biologics and novel agents.
Antoni Chan MD (Prof)
Tweet
22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026
sheila
Tweet
This retrospective cohort of NPSLE pts
showed clinical assocs with MRI findings: Pts w/ focal symptoms - abn MRI
Pts w/ diffuse symptoms - normal MRI except brain atrophy
Interesting to know how this can aid in future mgt strategies for NPSLE
OP093 @RheumNow #EULAR2026 https://t.co/omvdWk6EZK
Kicking off Clinical Abstracts: Comorbidities in RA session at #EULAR2026 with #OP084
ANCHOR-RA found 9.1% at-risk RA patients had previous undiagnosed ILD on screening HRCT. Older age, smoking, male sex & ⬆️DAS28 linked to RA-ILD. Important data for earlier detection @RheumNow
Janet Pope
Tweet
Does #Rx w #immunesuppression w
#antifibrotic
Help #SARD-ILD?
YES.
N=40 SARD-ILD, 1/2 w UIP pattern
Use of #IS w #antifibrotic pt group had better survival
Small N and ?channeling bias
But interesting results
TAke home : Use IS + antifibrotic
#EULAR2026 #POS0530
@RheumNow https://t.co/tfxVVw27jJ
#EULAR2026 POS0440 1-Year Open Label Extension Study of 6-monthly Inebilizumab, a CD19 depleter in #IgG4 disease:
-No flare in INEB group; 6% flare in PBO-INEB
-10.9% serious infections
-1 pt discontinued due to low IgG
Interested to see longer-term safety data @RheumNow https://t.co/PPUw81T8DZ
sheila
Tweet
Prof. Pedro Machado shares this important slide on a quick guide to #vaccination in patients w/ RMDs highlighting which vaccines are universally indicated, accdg to epidemiologic risk and w/ CIs.
#EULAR2026 @RheumNow https://t.co/JmTSC1uaph
#EULAR2026 General Assembly is ON!
Record-breaking 5'705 abstracts from 102 countries
187 scientific sessions ahead
@rheumnow https://t.co/0kAqND11L7
Congratulations to Professor Dennis McGonagle for being awarded the prestigious Heberden Oration Award at the 2026 British Society for Rheumatology (BSR) Conference. https://t.co/TOG5Y9tNrW https://t.co/3aumO6Z3A9
Join the global rheumatology community following RheumNow at #EULAR2026
✔️ Trusted faculty voices
✔️ Fast, curated insights
✔️ Clinically relevant takeaways
This is where rheumatology meets real-world practice. https://t.co/Hb88ZCP58P
Quiz Talk (5.22.2026)
Dr. Jack Cush talks of birthdays, quizzes, and journal articles this week on the podcast.
https://t.co/LwX0XxgPhn https://t.co/4uVTQo6NLG


